News

Children’s Hospital Los Angeles is recruiting Refractory Systemic Sclerosis Patients between 8 to 18 years of age for a Phase I/II pilot trial of the drug Campath-1H (ClinicalTrials.gov identifier: NCT01639573) to address whether prolonged administration of the drug can result in immunoablation. Campath-1H is a trade name…

Evidence is unclear about why some patients with systemic sclerosis (SSc) respond to treatment while others do not. However, a research team from Dartmouth was able to identify various biological pathways that are involved in different subsets of systemic sclerosis. Results from the research were published in two articles: the…

Findings from a recent study in mice suggest that neonatal colonization of gut microbiota influences generalized autoimmunity in adult life, which may have implications for conditions such as Systemic Lupus Erythematosus. Specifically, researchers from Ghent University Hospital in Belgium found that when there is an increase in the levels of…

Investigators at the University Hospital, Grenoble are currently recruiting participants for a new clinical trial on Raynaud’s Disease. (ClinicalTrials.gov Identifier: NCT01743612). The clinical trial titled “Laser SPEckle Contrast Imaging Interest in Detection of Cutaneous Microvascular Dysfunction in Systemic Sclerosis,” led by Jean-Luc CRACOWSKI, MD, PhDCIC,” was…

iBio, Inc. recently announced the release of a U.S. patent for a new thermostable immunomodulator protein portfolio called iBioModulator™. The company’s iBioModulator™ thermostable immunomodulator protein patents, entitled “Yersinia pests Antigens, Vaccine Compositions and Related Methods,” (Serial No. 8,945,580), includes statements about plague antigens, vaccine compositions, and a technique that produces…

Three key components of systemic sclerosis (SSc) are the subject of an ongoing clinical trial in University Hospital in Strasbourg, France. “Metabolomic Analysis of Systemic Sclerosis (SCLEROMICS)” is investigating prognosis, diagnosis, and exploratory research in SSc. Current knowledge in the field lacks a system of…

Emerging drug developer Corbus Pharmaceuticals Holdings, Inc. will be presenting its lead product candidate at the 17th Annual BIO CEO & Investor Conference taking place between February 9 and 10 at the Waldorf Astoria in New York. The investigational therapy, called Resunab, is meant to be…

Apricus Biosciences, Inc., a biopharmaceutical company committed to developing innovative medicines in the field of rheumatology and urology, recently announced that the United States Patent and Trademark Office (USPTO) issued the company a patent titled “Methods and compositions for treating Raynaud’s disease” with claims directed to treat Raynaud’s phenomenon. The patent will expire…

Botulinum toxin has been very popular for reducing wrinkles and more recently for treating painful conditions. The toxin may soon have a new use for another medical condition. Johns Hopkins University researchers are studying whether botulinum toxin can provide relief to people suffering from scleroderma-associated Raynaud’s Syndrome. Scleroderma is…

Systemic sclerosis (SSc) is a multisystem connective tissue disease characterized by vasculopathy and fibrosis. Pulmonary arterial hypertension (PAH) is one of the most severe organ complications and a leading cause of death in SSc. Estimations are that patients with SSc that have associated PAH have a 3-year survival of…